Innovating to treat disease more effectively
Our global Pharmaceuticals portfolio includes more than 40 key marketed products, many of which are innovative leaders in their therapeutic areas. In 2011 we received a total of 15 approvals in the United States, Europe and Japan.
Learn more about Novartis pharmaceuticals in your country:
Key pharmaceutical products marketed by Novartis are listed below in alphabetical order:
Lescol/Lescol XL (fluvastatin sodium)
Lotensin/Cibacen (benazepril hydrochloride)
Lotensin HCT/Cibadrex (benazepril hydrochloride and hydrochlorothiazide)
Lotrel (amlodipine besylate and benazepril hydrochloride)